🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

The sexually transmitted infection are on the rise worldwide, with estimates suggesting over 82 million instances per year. Notably increased rates are seen in Africa and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the context of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The global health body has designated it as a "high-priority threat". Ongoing monitoring found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Secure Authorization

Zoliflodacin, alternatively called a brand name, was authorized by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to major issues, including infertility. Experts hope that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in concurrent days. This treatment, which is additionally indicated for UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This approval marks a major breakthrough in the treatment of superbug gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Research Study Data and Global Access

Based on data detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This establishes an equal footing with the current standard treatment, which combines an injection and a pill. The study included nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the authority to make available and distribute the drug in numerous developing nations.

Doctors treating patients have expressed optimism. Having a single-dose, oral treatment of this kind is described as a "revolutionary step" for public health efforts. This is considered essential to reduce the burden of the disease for individuals and to halt the transmission of extremely resistant gonorrhoea worldwide.